Our unique business model allows us to stand out in a legal marketplace which is crowded with firms who look, act and think alike.
Choate, Hall & Stewart LLP Podcast
Claim This Podcastby Choate LLP
5.0(1 reviews)
28 episodes
Updated Weekly
Accepts GuestsHas SponsorsLocation 🇺🇸
Podcast Overview
Our unique business model allows us to stand out in a legal marketplace which is crowded with firms who look, act and think alike.
Language
🇺🇲
Publishing Since
6/15/2022
1 verified contact email on file for Choate, Hall & Stewart LLP Podcast
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
June 28, 2024
Research Security Enforcement Updates
<p> In this episode of the Enforcement and Investigations Podcast Series, Christine Savage and Mark McPherson discuss recent research security enforcement actions involving the University of Florida and Cleveland Clinic, as well as the biotechnology company Sigma-Aldrich. The discussion offers insights and takeaways from these matters that research security and compliance professionals can use to enhance their institutions’ research security programs, and highlights the impact of cooperating with the DOJ’s National Security Division Voluntary Self-Disclosure Program.</p>
June 27, 2024
Demystifying Private Investments
<p> In this episode of the Choate Family Office Services Podcast Series, Lanny Thorndike, President of Choate Investment Advisors, and Alison Svizzero, a Portfolio Manager and Head of Private Equity, explore the potential benefits of private equity investments for families looking to diversify their portfolios. The discussion covers how the addition of private equity investments to a portfolio can boost performance, broaden the opportunity offerings, and provide diversification benefits.</p>
May 1, 2024
Salix v. Norwich Patent Infringement Opinion and the Implications of a Post-Trial ANDA Amendment and Section 8 Carveout
<p>In this episode of our Life Sciences Insights podcast series, Sophie Wang and Madison Garrett discuss the Federal Circuit’s recent opinion in a patent infringement case between Salix Pharmaceuticals and Norwich Pharmaceuticals. The opinion arises out of Hatch-Waxman litigation concerning Norwich’s Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of Salix’s drug, rifaximin, marketed under the brand name Xifaxan®. Sophie and Madison discuss two main components of the opinion: (1) the use of a clinical trial protocol as prior art to render obvious a claim directed to a method of treatment with particular dosages, and whether that supports a reasonable expectation of success, and (2) the implications of a post-trial ANDA amendment with a section 8 carveout (a.k.a. skinny label) on an injunction order from the litigated case.</p>
28 total episodes available
Deep-dive analytics for Choate, Hall & Stewart LLP Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Choate, Hall & Stewart LLP Podcast?
- How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 6 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.